Short acting phenylalkylamine calcium channel blockers and uses thereof

A kit comprising

• (a) a pharmaceutical composition comprising a compound having the following structure:
• or a pharmaceutically acceptable addition salt thereof, or any enantiomer or diastereomer thereof, wherein
• each a, b, c, d, e, f, and g is, independently, —CH2—, —O—, —S—, or a single bond;
• each R11, R12, R13, R14, R15, R16, R17, and R20 is, independently:
• H, lower alkyl, lower alkyl substituted with —CO2 (lower alkyl), lower alkyl substituted with —CO2 (lower alkoxyalkyl), lower alkyl substituted with fluorine or chlorine, lower alkoxyalkyl, lower alkoxyalkyl substituted with —CO2 (lower alkyl), lower alkoxyalkyl substituted with —CO2 (lower alkoxyalkyl), lower alkoxyalkyl substituted with fluorine or chlorine, or CO2R10;
• each R10 is, independently, lower alkyl or lower alkoxyalkyl;
• R18 is H, CN, or CO2R10;
• and
• R19 is CH3 or H;
• and
• (b) instructions for using the pharmaceutical composition of (a) for the treatment of a condition selected from the group consisting of:
• ischemic heart conditions;
• cardiac arrhythmia;
• hypertensive crisis in an emergency room setting;
• hypertension before, during, or after surgery;
• no-reflow phenomenon following reperfusion;
• and
• a disease associated with decreased skeletal muscle flow;
• wherein the compound is not verapamil, gallopamil, emopamil, mepamil, or devapamil.

A method of treating an ischemic heart condition or cardiac arrhythmia, comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula

• or a pharmaceutically acceptable addition salt thereof, or any enantiomer or diastereomer thereof, wherein
• each a, b, c, d, e, f, and g is, independently, —CH2—, —O—, —S—, or a single bond;
• each R11, R12, R13, R14, R15, R16, R17, and R20 is, independently:
• H, lower alkyl, lower alkyl substituted with —CO2 (lower alkyl), lower alkyl substituted with —CO2 (lower alkoxyalkyl), lower alkyl substituted with fluorine or chlorine, lower alkoxyalkyl, lower alkoxyalkyl substituted with —CO2 (lower alkyl), lower alkoxyalkyl substituted with —CO2 (lower alkoxyalkyl), lower alkoxyalkyl substituted with fluorine or chlorine, or CO2R10;
• each R10 is, independently, lower alkyl or lower alkoxyalkyl;
• R18 is H, CN, or CO2R10;
• and
• R19 is CH3 or H;
• wherein the compound is not verapamil, gallopamil, emopamil, mepamil, or devapamil.

A method of treating a hypertensive crisis in an emergency room setting, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula

• or a pharmaceutically acceptable addition salt thereof, or any enantiomer or diastereomer thereof, wherein
• each a, b, c, d, e, f, and g is, independently, —CH2, —O—, —S—, or a single bond;
• each R11, R12, R13, R14, R15, R16, R17, and R20 is, independently:
• H, lower alkyl, lower alkyl substituted with —CO2 (lower alkyl), lower alkyl substituted with —CO2 (lower alkoxyalkyl), lower alkyl substituted with fluorine or chlorine, lower alkoxyalkyl, lower alkoxyalkyl substituted with —CO2 (lower alkyl), lower alkoxyalkyl substituted with —CO2 (lower alkoxyalkyl), lower alkoxyalkyl substituted with fluorine or chlorine, or CO2R10;
• each R10 is, independently, lower alkyl or lower alkoxyalkyl;
• R18 is H, CN, or CO2R10;
• and
• R19 is CH3 or H;
• wherein the compound is not verapamil, gallopamil, emopamil, mepamil, or devapamil.

A method of treating hypertension before, during, or after surgery, or no-reflow phenomenon following reperfusion, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula

• or a pharmaceutically acceptable addition salt thereof, or any enantiomer or diastereomer thereof, wherein
• each a, b, c, d, e, f, and g is, independently, —CH2—, —O—, —S—, or a single bond;
• each R11, R12, R13, R14, R15, R16, R17, and R20 is, independently:
• H, lower alkyl, lower alkyl substituted with —CO2 (lower alkyl), lower alkyl substituted with —CO2 (lower alkoxyalkyl), lower alkyl substituted with fluorine or chlorine, lower alkoxyalkyl, lower alkoxyalkyl substituted with —CO2 (lower alkyl), lower alkoxyalkyl substituted with —CO2 (lower alkoxyalkyl), lower alkoxyalkyl substituted with fluorine or chlorine, or CO2R10;
• each R10 is, independently, lower alkyl or lower alkoxyalkyl;
• R18 is H, CN, or CO2R10;
• and
• R19 is CH3 or H;
• wherein the compound is not verapamil, gallopamil, emopamil, mepamil, or devapamil.

A method of treating a disease associated with decreased skeletal muscle blood flow, said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound having the formula

• or a pharmaceutically acceptable addition salt thereof, or any enantiomer or diastereomer thereof, wherein
• each a, b, c, d, e, f, and g is, independently, —CH2—, —O—, —S—, or a single bond;
• each R11, R12, R13, R14, R15, R16, R17, and R20 is, independently:
• H, lower alkyl, lower alkyl substituted with —CO2 (lower alkyl), lower alkyl substituted with —CO2 (lower alkoxyalkyl), lower alkyl substituted with fluorine or chlorine, lower alkoxyalkyl, lower alkoxyalkyl substituted with —CO2 (lower alkyl), lower alkoxyalkyl substituted with —CO2 (lower alkoxyalkyl), lower alkoxyalkyl substituted with fluorine or chlorine, or CO2R10;
• each R10 is, independently, lower alkyl or lower alkoxyalkyl;
• R18 is H, CN, or CO2R10;
• and
• R19 is CH3 or H;
• wherein the compound is not verapamil, gallopamil, emopamil, mepamil, or devapamil.